Phase I/II trial of BL 8040 in combination with sorafenib in AML patients with FLT3-ITD mutation

Trial Profile

Phase I/II trial of BL 8040 in combination with sorafenib in AML patients with FLT3-ITD mutation

Planning
Phase of Trial: Phase I/II

Latest Information Update: 19 May 2016

At a glance

  • Drugs BL 8040 (Primary) ; Sorafenib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors BioLineRx
  • Most Recent Events

    • 19 May 2016 According to a BioLineRx Ltd. media release, the company will present results of this Phase 2a study at the European Hematology Association 21st Congress. Also, the detailed results from this Phase 2a study will be presented at an upcoming US-based scientific conference.
    • 10 Mar 2016 Planned initiation date changed from 1 Mar 2015 to 1 Jul 2016, as per BioLineRx media release.
    • 17 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top